Serum Levels of Sulpiride Enantiomers after Oral Treatment with Racemic Sulpiride in Psychiatric Patients: a Pilot Study[1]

Sulpiride (SULP), a substituted benzamide with high selectivity for D₂-like dopamine receptors, has a chiral structure and is used in most countries as the racemate. In an open pilot study, we investigated 26 inpatients (13 female, 13 male) with schizophrenic or depressive disorder treated with SULP (mean daily dosage 64 - 1062 mg) administered orally, either as a monotherapy or as an add-on treatment to a stable and unchanged medication for 3 - 60 days. Serum levels of total SULP and of its enantiomers were measured by high-performance liquid chromatography (HPLC) procedures. Clinically relevant indicators of hepatic and renal function as well as retrospectively assessed clinical outcome parameters were correlated with serum levels of racemic SULP, L-SULP, D-SULP, and the L : D-SULP ratio. A significant correlation between mean daily dosage and serum levels of SULP, L-SULP, and D-SULP emerged (p < 0.05) which was not influenced by age, gender, diagnosis, hepatic, or renal function. The ratio of L : D-SULP serum levels was < 1 (range 0.66 - 0.97) in all patients. A slight negative correlation between CGI improvement and the ratio of L : D-SULP (p < 0.10) and a positive correlation between racemic SULP concentrations and side-effects at endpoint was found (p < 0.05).

1 Preliminary results of the present paper were presented at the XI. Congress of the World Psychiatric Association, September 1999, Hamburg, Germany

References

• 1 Benkert O, Holsboer F. Effect of sulpiride in endogenous depression.  Acta Psychiatr Scand. 1984;  311 43-48
• 2 Bressolle F, Faure-Jeantis A. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans.  J Pharm Sci. 1992;  81 26-32
• 3 Collegium Internationale Psychiatriae Scalarum (CIPS). Weinheim; Beltz 1988
• 4 Crescimanno G, Sorbera F, Emmi A, Amato G. Inhibitory effect of A10 dopaminergic neurons of the ventral tegmental area on the orienting response evoked by acoustic stimulation in the cat.  Brain Res Bull. 1998;  45 61-65
• 5 Dahl S G. Pharmacokinetics of neuroleptic drugs and the utility of plasma level monitoring.  Psychopharmacol Ser. 1988;  5 34-46
• 6 Dahl S G. Plasma level monitoring of antipsychotic drugs. Clinical utility.  Clin Pharmacokinet. 1986;  11 36-61
• 7 Edwards J G, Alexander J R, Alexander M S, Gordon A, Zutchi T. Controlled trial of sulpiride in chronic schizophrenia.  Br J Psychiatry. 1980;  137 522-529
• 8 Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and serum concentrations.  Br J Psychiatry. 1983;  147 283-288
• 9 Lane R M, Baker G B. Chirality and drugs used in psychiatry: nice to know or need to know?.  Cell Mol Neurobiol. 1999;  19 355-372
• 10 Maier W, Benkert O. Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.  Psychopharmacology. 1994;  115 495-501
• 11 Mauri M C, Bitetto A, Fabiano L, Laini V, Steinhilber C, Fornier M, Rafique F. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs.  Prog Neuropsychopharmacol Biol Psychiatry. 1999;  23 43-54
• 12 Mucci A, Nolfe G, Maj M. Levosulpiride: a review of its clinical use in psychiatry.  Pharmacol Res. 1995;  31 95-101
• 13 Polatti F. Sulpiride isomers and milk secretion in puerperium.  Clin Exp Obstet Gynecol. 1982;  9 144-147
• 14 Rao V A, Bailey J, Bishop M, Coppen A. A clinical and pharmacodynamic evaluation of sulpiride.  Psychopharmacology. 1981;  73 77-80
• 15 Rietbrock S, Merz P G, Fuhr U, Harder S, Marschner J P, Loew D, Biehl J. Absorption behavior of sulpiride described using Weibull functions.  Int J Clin Pharmacol Ther. 1995;  33 299-303
• 16 Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder - the spontaneously hypertensive rat.  Brain Res. 1995;  676 343-351
• 17 Rüther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.  Pharmacopsychiat. 1999;  32 127-135
• 18 Seeman P. Dopamine receptors: Clinical correlates. In: Bloom FE, Kupfer DJ, editors Psychopharmacology: The fourth generation of progress. New York; Raven Press 1995: 295-302
• 19 Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.  Br J Psychiatry. 1995;  171 569-573
• 20 Tokunaga H, Kudo K, Imamura T, Jitsufuchi N, Ohtsuka Y, Ikeda N. Plasma concentrations of antipsychotic drugs in psychiatric inpatients.  Nippon Hoigaku Zasshi. 1997;  51 417-422
• 21 Tokunaga H, Kudo K, Jitsufuchi N, Ohtsuka Y, Imamura T. Sensitive determination of sulpiride in human plasma by high-performance liquid chromatography.  J Chromatogr B Biomed Sci Appl. 1997;  691 203-207
• 22 Vergoni A V, Forgione A, Bertolini A. Chronic administration of l-sulpiride at non-neuroleptic doses reduces the duration of immobility on experimental models of “depression-like” behavior.  Psychopharmacology. 1995;  121 279-281
• 23 Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action.  Int Clin Psychopharmacol. 1997;  12 (Suppl 3) S7-S14

1 Preliminary results of the present paper were presented at the XI. Congress of the World Psychiatric Association, September 1999, Hamburg, Germany